Search company, investor...


Founded Year



Asset Sale | AssetsPurchased

Total Raised


About Archemix

Archemix discovers, develops, and commercializes therapeutic aptamers for the prevention and treatment of chronic and acute diseases. The Company's aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. The company also offers product candidates for cardiovascular, hematology, and oncology diseases.

Headquarters Location

601 Montgomery Street Suite 2020

San Francisco, California, 94111,

United States


Missing: Archemix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Archemix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Archemix Patents

Archemix has filed 27 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Complement system
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Complement system, Immune system, Immunology, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Clusters of differentiation, Complement system, Immune system, Immunology, Monoclonal antibodies



Latest Archemix News

$10 Million available to Patient Monitoring Engineering Team

Jun 18, 2018

What he’s backed: AccentCare, Archemix, Yoga Works What he wants now: An engineering team to design implantable wireless devices capable of 24⁄7 patient and data monitoring for conditions such as heart disease and diabetes. Companies like Medtronic and Boston Scientific have multibillion-dollar R&D pipelines for medical devices but are increasingly finding it cheaper to simply acquire early-stage companies–so a startup need only get a product to an early testing stage, and can then let a bigger player worry about taking it commercial. Mulloy considers implantable hardware an ideal target market, since it can exploit recent advances in low-power wireless chipsets, materials, and microelectromechanical systems, or MEMS. A device designed to monitor a diabetic patient, for instance, might trigger a bedside alarm for spikes in blood sugar levels, send continuous data to a doctor, or both. “HMOs are looking for ways to proactively manage individual diseases like congestive heart failure and diabetes,” Mulloy says. “These kinds of devices take us toward that.” What he’ll invest: $10 million over three years for a functioning prototype, software to manage wireless data, and early-stage trials Send your pitch to:  and don’t forget to CC me .

Archemix Frequently Asked Questions (FAQ)

  • When was Archemix founded?

    Archemix was founded in 2000.

  • Where is Archemix's headquarters?

    Archemix's headquarters is located at 601 Montgomery Street, San Francisco.

  • What is Archemix's latest funding round?

    Archemix's latest funding round is Asset Sale.

  • How much did Archemix raise?

    Archemix raised a total of $116.5M.

  • Who are the investors of Archemix?

    Investors of Archemix include Baxter, U.S. Trust, Lumira Ventures, Rho Ventures, Prospect Venture Partners and 12 more.

  • Who are Archemix's competitors?

    Competitors of Archemix include DiscoveryBioMed, InterveXion Therapeutics, Proteostasis Therapeutics, GettingHired, Cellzome and 10 more.

Compare Archemix to Competitors


Therasis Inc. is a new drug discovery company developing oncology therapeutics for use as single agents or in combination therapy.

De Novo Pharmaceuticals

De Novo Pharmaceuticals Ltd is a computationally-based drug discovery company focused on small molecule therapeutics. De Novo develops a suite of structure-generating programs called SkelGen. The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ. Ninety-percent of the structures produced by SkelGen is chemically tractable.


Priaxon is a research company focusing on drug discovery for small molecule therapeutics.

InVasc Therapeutics

InVasc Therapeutics specializes in target-specific drug discovery and has developed a approach to drug discovery that uses molecular structures and an application-based platform that decreases the time and expense of current large-scale "mining"� discovery techniques. The InVasc process is the result of university-based research at Emory University and The Ohio State University.

Molecular LogiX

Molecular LogiX (MLX) is a drug discovery company located in The Woodlands, Texas, that seeks to discover therapeutics through the application of rationale protein engineering technologies. The company is currently developing protein-based drugs to treat cancer by interfering with established tumor growth factor pathways.

Carmot Therapeutics

Carmot Therapeutics is a clinical-stage biotechnology company. It is focused on the discovery and development of disease-modifying therapies for people living with metabolic diseases including obesity and diabetes. It utilizes Chemotype Evolution, a pioneering drug discovery platform, to identify novel incretin receptor signaling targets and develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. The company was founded in 2008 and is based in Berkeley, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.